Back
Akeso Cancer Drug Ivonescimab Wins Fifth Breakthrough Designation
Back
Stock News
Themes
Akeso Cancer Drug Ivonescimab Wins Fifth Breakthrough Designation
Akeso Cancer Drug Ivonescimab Wins Fifth Breakthrough Designation
Edgen Stock
·
Feb 06 2026, 11:28
Share to
Share to
Copy link
AKESO
-0.09%
source:
[1] Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
Recommend
Apple Stock Climbs as Investors Shun Big Tech's $650B AI Spending
Feb 18 2026, 00:32
Similarweb Swings to Profit, Beating Q4 Estimates
Feb 17 2026, 23:58
Hormel Sells Turkey Business, Reaffirms 2026 Guidance
Feb 17 2026, 23:57
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Feb 06 2026, 11:28Edgen Stock·Feb 06 2026, 11:28
Edgen Stock·Feb 06 2026, 11:28